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Abstract
Background: Traumatic brain injury is a major cause of death and severe disability worldwide with 1,000,000
hospital admissions per annum throughout the European Union.
Therapeutic hypothermia to reduce intracranial hypertension may improve patient outcome but key issues are
length of hypothermia treatment and speed of re-warming. A recent meta-analysis showed improved outcome
when hypothermia was continued for between 48 hours and 5 days and patients were re-warmed slowly (1°C/4
hours). Previous experience with cooling also appears to be important if complications, which may outweigh the
benefits of hypothermia, are to be avoided.
Methods/design: This is a pragmatic, multi-centre randomised controlled trial examining the effects of
hypothermia 32-35°C, titrated to reduce intracranial pressure <20 mmHg, on morbidity and mortality 6 months
after traumatic brain injury. The study aims to recruit 1800 patients over 41 months. Enrolment started in April
2010.
Participants are randomised to either standard care or standard care with titrated therapeutic hypothermia.
Hypothermia is initiated with 20-30 ml/kg of intravenous, refrigerated 0.9% saline and maintained using each
centre’s usual cooling technique. There is a guideline for detection and treatment of shivering in the intervention
group. Hypothermia is maintained for at least 48 hours in the treatment group and continued for as long as is
necessary to maintain intracranial pressure <20 mmHg. Intracranial hypertension is defined as an intracranial
pressure >20 mmHg in accordance with the Brain Trauma Foundation Guidelines, 2007.
Discussion: The Eurotherm3235Trial is the most important clinical trial in critical care ever conceived by European
intensive care medicine, because it was launched and funded by the European Society of Intensive Care Medicine
and will be the largest non-commercial randomised controlled trial due to the substantial number of centres
required to deliver the target number of patients. It represents a new and fundamental step for intensive care
medicine in Europe. Recruitment will continue until January 2013 and interested clinicians from intensive care units
worldwide can still join this important collaboration by contacting the Trial Coordinating Team via the trial website
http://www.eurotherm3235trial.eu.
Trial registration: Current Controlled Trials ISRCTN34555414
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Background
Traumatic brain injury (TBI) is a major cause of death
and severe disability throughout the world. TBI leads to
1,000,000 hospital admissions per annum throughout
the European Union. It causes the majority of the
50,000 deaths from road traffic accidents and leaves
10,000 patients severely handicapped: three quarters of
these victims are young people [1]. Additionally, TBI
causes 290 000 hospital admissions, 51 000 deaths and
leaves 80 000 patients with permanent neurological dis-
abilities in the United States annually [2]. The conse-
quence of this is both a devastating emotional and
physical impact and an enormous financial burden [3].
Therapeutic hypothermia has been shown to improve
outcome after cardiac arrest [3], consequently the Eur-
opean Resuscitation Council and American Heart Asso-
ciation guidelines [4,5] recommend the use of
hypothermia in these patients. Hypothermia is also
thought to improve neurological outcome after neonatal
birth asphyxia [6]. Cardiac arrest and neonatal asphyxia
patient populations present to health care services
rapidly and without posing a diagnostic dilemma,
therefore therapeutic systemic hypothermia may be
implemented relatively quickly. As a result of this,
hypothermia in these two populations is similar to
laboratory models where systemic therapeutic hypother-
mia is commenced very soon after the injury and has
shown so much promise [7].
The need for resuscitation and Computerised Tomo-
graphy (CT) imaging to confirm the diagnosis in
patients with TBI, are factors which delay intervention
with temperature reduction strategies. Treatments in
TBI have traditionally focussed on restoring and main-
taining adequate brain perfusion, surgically evacuating
large haematomas where necessary, and preventing or
promptly treating oedema [3]. Brain swelling can be
monitored by measuring intracranial pressure (ICP), and
in most centres ICP is used to guide treatments and to
monitor their success. The use of hypothermia in TBI
should be regarded in this context.
Pathophysiology
Ischaemia has a key role in all forms of brain injury and
preventing ischaemic (or secondary) injury is at the core
of all neuroprotective strategies [3]. A complex cascade
of processes ensues at the cellular level after a period of
ischaemia beginning from minutes to hours after injury
and continuing for up to 72 hours or longer. Thus,
there may be a window of opportunity of several hours,
or even days, during which injury can be mitigated by
treatments such as hypothermia [3].
Review of Clinical Evidence
In total, 29 clinical studies have been performed to assess
the effects of hypothermia in TBI. Twenty-seven of these
were performed in adult patients, 18 of which included
control groups. Data from one pilot study were subse-
quently included in a larger study, therefore leaving 17
studies. As outlined above, study protocols have differed
considerably, and not all studies were (properly) rando-
mised [3]. A total of 131 patients were enrolled into two
studies undertaken in patients with normal ICP. Only
one of these studies reported outcome data (at 3 months)
and the results showed no significant difference between
groups (good outcome in 21/45 (hypothermia) versus
27/46 patients (controls), p = 0.251) [8].
Eighteen studies, with outcome data available for 2096
patients, used hypothermia in patients with high ICP
that was refractory to “conventional” treatments (usually
sedation/analgesia, muscle relaxants, osmotic therapy,
and sometimes barbiturates) [9-26]. The results are
summarised in Figure 1. All observed decreases in ICP
during cooling. Thirteen of these studies reported signif-
icant improvements in outcome associated with
hypothermia [10,12-14,16,17,19-25]. All of these were
performed in specialised neurotrauma centres, with
experience in applying hypothermia and managing
its side effects. Ten were single centre studies
[10,12,14,16,17,20,22-25], three (all performed in China)
[14,20,22] were multi-centre. Four additional studies
[11,15,18,21] observed a trend to improved outcome,
but these differences were not statistically significant.
Interpretation of these results is complicated by the
fact that these studies have enrolled different categories
of patients, with different types of injuries, and have
used widely diverging treatment protocols [27]. Most
have used elevated ICP as an inclusion criterion
although some have used CT-scan criteria. The duration
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Figure 1 Stages of therapeutic management of raised
intracranial pressure after traumatic brain injury [37,43].
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of cooling varied from 24 hours to more than five days
and re-warming rates have also varied. Some studies
have used ICP to guide depth and duration of treatment
although responses to rebound intracranial hypertension
have differed [3]. Use of co-interventions such as osmo-
tic therapy, sedation, analgesia, paralysis, targets for
mean arterial pressure and cerebral perfusion pressure
(CPP) have also varied considerably [3]. All of these fac-
tors can affect outcome after TBI in general, and the
potential efficacy of cooling in particular. Thus inter-
preting, comparing and aggregating the results of these
studies presents a number of complex challenges.
In contrast, one of the two largest multi-centre rando-
mised controlled trials (RCTs) failed to show that thera-
peutic hypothermia improved outcome at 6 months
after TBI (Relative Risk (RR) of a poor outcome 1; 95%
CI 0.8-1.2; p = 0.99) [9]. Significantly more of the
patients admitted to hospital with hypothermia who
were randomised to normothermia, and consequently
re-warmed, had a poor outcome (78% n = 31). Com-
pared to patients admitted with hypothermia and treated
with hypothermia (61% n = 38) (p = 0.09).
On subsequent analysis, it became clear that although
this study was methodologically well designed, there
was marked inter-centre variance in the treatment
effect of hypothermia, age of participants, severity of
illness scoring between groups, management of intra-
cranial hypertension and haemodynamic and fluid
management [28]. Therapeutic hypothermia in the
hypothermia group was started relatively late with a
slow speed of cooling (average time to target tempera-
ture >8 hours) in all centres.
Hypotension (lasting >2 hours) and hypovolaemia
occurred three times more frequently in the hypother-
mia group. Bradycardia associated with hypotension also
occurred four times more frequently in this group, elec-
trolyte disorders and hyperglycaemia were also found
more frequently in the hypothermia group [9]. All of
these complications are known side effects of hypother-
mia. Most are easily preventable with good intensive
care and should not be regarded as inevitable conse-
quences of hypothermia treatment. Since even very brief
episodes of hypotension or hypovolaemia can adversely
affect outcome in TBI, these and other issues may have
significantly affected the results of this trial [29-31]. One
possible problem was that some of the participating cen-
tres had little or no previous experience in using
hypothermia. Large centres, familiar with cooling,
showed apparently favourable neurological outcomes
whereas smaller centres showed poor outcomes.
Induction of Hypothermia
The most widely accepted use of hypothermia in adults
is after cardiac arrest. Two RCTs in this patient group
have shown significant neurological improvements in
patients treated with hypothermia many hours after
injury, whose initial cardiac rhythm was ventricular
fibrillation or ventricular tachycardia [32,33]. Subsequent
data from a large study of patients after myocardial
infarction suggest that infarct size was reduced in
patients who were cooled to <35°C before coronary
intervention [34]. This suggests that faster cooling rates
may be beneficial to patient outcome.
Methods of cooling can be broadly divided into sur-
face and core cooling techniques [35]. The study of
patients after myocardial infarction used surface cooling
devices alone and found that large numbers of patients
did not reach target temperature quickly enough before
the start of the coronary intervention [34]. Despite
advancing technology in surface cooling devices and the
introduction of endovascular catheters for core cooling,
average periods of 2-3 hours are still required to reach
temperatures of 32-34°C [35]. The currently available
surface cooling devices are also relatively large and cum-
bersome. This, coupled with the need for staff with spe-
cialist knowledge of the management of therapeutic
hypothermia, may prevent its use outside of an Intensive
Care Unit (ICU) [35].
A recent study examined the feasibility, speed and
complication rates of infusing refrigerated fluids intrave-
nously to quickly induce hypothermia in patients with
various neurological injuries [35]. Results showed that a
1500 ml infusion of 0.9% saline, administered over 30
minutes, in patients without cardiac shock, reduced core
temperature from 36.9 ± 1.9°C to 34.6 ± 1.5°C at 30
minutes and to 32.9 ± 0.9°C at 60 minutes. Continuous
monitoring of arterial blood pressure, heart rhythm,
central venous pressure, arterial blood gasses and serum
levels of electrolytes, platelets and white blood cells
showed no significant adverse events [35].
When hypothermia develops, the body will immedi-
ately try to counteract the temperature drop to maintain
homeostasis [36]. One of the key mechanisms of heat
production is shivering which can lead to an increased
oxygen consumption of 40%-100% which may be detri-
mental in this patient population. Sedation drugs are
known to increase peripheral blood flow which, in turn,
will increase the transfer of heat from the core to the
peripheries, thus reducing core temperature [36]. There-
fore shivering may be counteracted by the administra-
tion of sedatives, anaesthetic agents, opiates and/or
muscle relaxants [36].
It should be noted however, that the capacity and
effectiveness of the mechanisms of controlling body
temperature decrease with age. Younger patients will
therefore react earlier and with greater intensity than
older patients. For this reason, induction of hypother-
mia in younger patients often requires high doses of
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sedation drugs to counteract the counter-regulatory
mechanisms [36].
Meta-analyses
Six meta-analyses have been published between the
years 2000 and 2008 [37-42]. These included various
numbers of trials, with varying quality of randomisation
and blinding procedures. All found a trend to positive
effects of hypothermia on neurological outcome,
although statistical significance was reached in only two
reviews: RR of improved neurological outcome 0.78 (95%
CI 0.63-0.98) [37] and RR 0.68 (95% CI 0.52-0.89) [38].
The most recent meta-analysis [42] included eight
trials which studied comparable patient groups at base-
line. Hypothermia was shown to reduce mortality by
20% although this was not statistically significant (RR
0.80; 95% CI 0.59-1.09). Subgroup analysis showed that
this effect was significantly greatest when hypothermia
was maintained for >48 hours (RR 0.51; 95% CI 0.33-
0.79). Hypothermia was also associated with a non-sig-
nificant increase of 25% in neurological outcome when
measured by the Glasgow Outcome Scale (GOS) at 6
months (RR 1.25; 95% CI 0.96-1.62). Despite not reach-
ing statistical significance, results showed an increased
likelihood of improved neurological outcome when cool-
ing was maintained for >48 hours (RR 1.91; 95% CI
1.28-2.85). Another key finding of this meta-analysis was
that hypothermia was only of significant benefit to those
patients who had not received barbiturate therapy (RR
0.58 95% CI 0.40-0.85).
A criticism of these meta-analyses is that most failed to
take account of important differences in patient groups
(such as those with or without intracranial hypertension)
and of differences in treatment protocols, except the use
of hypothermia. Only one differentiated between studies
that enrolled patients with normal ICP and those that
enrolled patients with intracranial hypertension and found
no neurological improvement associated with hypothermia
[41]. Two assessed effects of treatment duration and speed
of re-warming [37,38], concluding that cooling for
>48 hours and re-warming rates of 24 hours, or 1°C/4
hours, were both key factors in reducing mortality
(RR 0.70; 95% CI, 0.56-0.87) and improving neurological
outcome (RR, 0.79; 95% CI 0.63-0.98) respectively.
Rationale for Study
The evidence from previous research shows that treat-
ment with therapeutic hypothermia to reduce intracra-
nial hypertension may improve patient outcome after
TBI. A recent meta-analysis has shown key relationships
between the duration of hypothermia treatment and
speed of re-warming with patient outcome [42].
Improved patient outcome was found when hypother-
mia was continued for between 48 hours and 5 days and
patients were re-warmed slowly (1°C/4 hours). Experi-
ence with cooling also appears to be important if com-
plications which may outweigh the benefits of
hypothermia are to be avoided.
The Eurotherm3235Trial is examining the relationship
between therapeutic hypothermia for ICP reduction
after TBI and patient outcome. The trial is enrolling
patients with TBI who have ICP >20 mmHg that is
resistant to stage 1 therapy (Figure 1).
The Brain Trauma Foundation’s recommended thresh-
old for treatment of ICP is 20 mmHg [37,43]. Although
early cooling after injury is considered to be beneficial,
this is offset by failure to show benefit from hypother-
mia in the absence of raised ICP. Enrolment to the trial
is therefore allowed for up to 72 hours following injury.
This potential delay in cooling is compensated for, to an
extent, by inducing hypothermia with 20-30 ml/kg of
refrigerated 0.9% saline given intravenously over 20-30
minutes. No maximum duration of cooling is specified
and hypothermia can continue until ICP is no longer
dependent on temperature reduction to remain below
20 mmHg. Patients are then slowly re-warmed at a rate
of 0.25°C per hour (1°C/4 hours).
The Extended Glasgow Outcome Scale (GOSE) is used
to assess patient outcome at 6 months. Many patients
with severe TBI are expected to have poor outcome.
This outcome questionnaire is used as it is more sensi-
tive to differences between poorer outcome categories
after TBI than the 5-point Glasgow Outcome Score
(GOS) [44,45].
Study Objectives
Hypothesis
Patients treated with therapeutic hypothermia (32-35°C)
have reduced morbidity and mortality rates compared to
those receiving standard care alone after TBI.
Research Questions
Does therapeutic hypothermia (32-35°C) reduce morbid-
ity and mortality rates at 6 months after TBI assessed
by the GOSE questionnaire?
Does therapeutic hypothermia (32-35°C) reduce intra-
cranial hypertension?
Is therapeutic hypothermia a costeffective treatment to
improve outcome after TBI?
Study Endpoints
Primary
• Outcome at 6 months using the GOSE questionnaire
Other
• 6 month mortality rate
• ICP control
• Incidence of pneumonia across both groups
• Length of stay in the ICU and hospital
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• Modified Oxford Handicap Scale score at one
month, discharge from the randomising hospital or
death, whichever occurs first
• Correlation between the predicted outcome using
the modified Oxford handicap scale at hospital dis-
charge and the GOSE Score at 6 months post injury
• Health economics (dependent on additional exter-
nal funding).
Methods/design
This is a pragmatic, multi-centre randomised controlled
trial to examine the effects of hypothermia (32-35°C) on
outcome after traumatic brain injury. The study is
recruiting for 41 months. Participants are randomised to
either the control or intervention group (Figure 2). Par-
ticipants allocated to the control group receive standard
care without therapeutic hypothermia. Participants ran-
domised to the intervention group receive standard care
with therapeutic hypothermia. Hypothermia is initiated
with 20-30 ml/kg refrigerated 0.9% saline given intrave-
nously and maintained using the cooling technique
available at that centre. A flowchart has been designed
for the induction and maintenance of therapeutic
hypothermia in the intervention group. The depth of
hypothermia (range: 32-35°C) is guided by ICP with a
higher pressure level warranting a cooler target tem-
perature. A guideline has been produced for the detec-
tion and treatment of shivering in the intervention
group. This has been designed specifically for this trial
drawing on:
• the hospital protocol of the Mission Hospital,
Orange County California (permission given by
Mary Kay Bader, Neuro Clinical Nurse Specialist,
Mission Hospital, Orange County, Ca, USA)
• The hospital protocol of the University Medical
Centre, Utrecht, The Netherlands (permission given
by Dr Kees Polderman, UMC, Utrecht, The
Netherlands)
• The Bedside Shivering Assessment Scale [46]
Therapeutic hypothermia of 32-35°C is maintained for
at least 48 hours in the treatment group. Previous stu-
dies have shown that therapeutic hypothermia which
lasts for at least 48 hours shows a trend to reduction in
mortality and improved neurological function after TBI
[42]. Hypothermia is continued for as long as is neces-
sary to reduce and maintain ICP <20 mmHg. Intracra-
nial hypertension is defined as an ICP >20 mmHg by
the Brain Trauma Foundation Guidelines [37]. Together
with therapeutic hypothermia, all patients in the inter-
vention group continue to be treated with stage 1 and 2
therapies as required to reduce intracranial hypertension
[37,38]. If raised ICP becomes resistant to these thera-
pies and despite increasing the depth of hypothermia,
care may be escalated to include stage 3 interventions.
If this is required, therapeutic hypothermia treatment
should be terminated for patients allocated to the
treatment group and the patient re-warmed using the
re-warming guideline. The reason for treatment escala-
tion should be documented on the daily data collection
form.
The primary endpoint of the Eurotherm3235Trial is
outcome 6 months after TBI using the GOSE question-
naire. Participants are sent the GOSE questionnaire with
a covering letter by post 6 months after randomisation
by the coordinating centre.
Study Population
Sample Size
A total of 1800 patients (900 per treatment group) will
be enrolled. At least 70 hospitals specialising in the care
of TBI patients will be initiated worldwide including
centres in Belgium, Germany, Italy, Netherlands, Spain,
Sweden and the United Kingdom.
Inclusion Criteria
1) Believed to be legal age for consent to take part in
research to 65 years of age
2) Primary closed TBI
3) Raised ICP >20 mmHg for ≥5 minutes after first
line treatments with no obvious reversible cause e.g.
patient position, coughing, inadequate sedation
4) ≤72 hours from the initial head injury
5) Cooling device or technique available for >48
hours
6) Core temperature ≥36°C (at the time of
randomisation)
7) An abnormal CT scan of the brain. This is
defined as one that shows haematoma, contusion,
swelling, herniation or compressed basal cisterns.
Exclusion Criteria
1) Patient already receiving therapeutic hypothermia
treatment
2) Administration of barbiturate infusion prior to
randomisation
3) Unlikely to survive for the next 24 hours in the
opinion of the ICU Consultant or Consultant Neuro-
surgeon treating the patient
4) Temperature ≤34°C at hospital admission
5) Pregnancy (all female patients of child bearing age
who meet the inclusion criteria will undergo a urine
pregnancy test. This is performed as part of the
screening for eligibility procedure by the investigator
or research nurse in the ICU).
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Figure 2 Eurotherm3235Trial study flowchart.
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Participant Selection and Enrolment
Identifying Participants
Eligible participants are identified by nursing and medi-
cal staff on the ICU.
Consenting Participants
Eligible patients for this study must have raised ICP
despite stage 1 treatment options for the management
of head injury. Stage 1 treatment options include seda-
tion and ventilation therefore participants are not be
able to give informed consent themselves.
The patient and relative information sheets were
designed in consultation with patients who had suffered
a TBI and their relatives. Consultations took place at
the drop-in centre for the Edinburgh Headway Group, a
registered charity for brain injured patients http://www.
edinburghheadway.org.uk.
Screening for Eligibility
A screening log is completed for all eligible patients.
Data including inclusion criteria met, exclusion criteria
not met and date consent obtained are collected on this
form. It is kept in a locked cabinet at the centre. This
data are slso entered in the trial database via the electro-
nic case report form (CRF) in order for the trial office to
monitor recruitment and/or refusal rates at each site.
Randomisation
Patients should be randomised as soon as possible after
meeting the inclusion criteria. The randomisation of
participants to hypothermia or standard care is underta-
ken using either a central internet based randomisation
service or a telephone randomisation service depending
on the available technology at each site.
Treatment allocation is minimised using the following
baseline covariates (but includes a random element to
ensure allocation concealment):
1) Trial Centre
2) Age < or ≥45 years
3) Post-resuscitation Glasgow Coma Score motor
component 1-2 or 3-6
4) Time from injury < or ≥12 hours
5) Pupils: both reacting or 1 or neither reacting
Treatment Allocation
It is not possible to blind local investigators to allocation
as it is obvious clinically which patients are receiving
hypothermia e.g. equipment required, patient tempera-
ture, blood results, fluid requirements. Blinding of out-
come data assessment is however be ensured as the
GOSE questionnaire is posted to participants by the
coordinating centre.
Premature Withdrawal
Participation in any research trial is voluntary and there-
fore the participant or their legal representative may
wish to withdraw from the trial at any point. If this is
the case, it should be made clear on a Premature With-
drawal Form whether any previously collected data may
still be used for the analysis and which part of the trial
the patient is being withdrawn from:
1)Withdraw entirely - the hypothermia intervention
is safely terminated, no further data is collected and
previous data collected will not be used in the
analysis.
2)Withdraw entirely - no further data is collected
and the intervention is safely terminated but data
previously collected may be used in the analysis.
3)Withdraw from the intervention but be willing to
be followed up.
4)Withdraw from being followed up only.
If the patient wishes to withdraw from the trial or
their legal representative wishes to withdraw them, they
are free to do so without giving a reason and without
the patient’s medical care or legal rights being affected
[47]. If however the patient is withdrawn from the study
by the doctor in charge of their care on medical
grounds, the reason for this withdrawal must be clearly
documented in the data collection form and a serious
adverse event form completed if appropriate.
Data Collection and Checking
Daily data collection starts on the day of randomisation
(baseline) for all patients and continues until the ICP
monitor has been removed. Data is collected using an
electronic CRF. This includes the Modified Oxford Han-
dicap Scale which is completed at hospital discharge.
Paper copies of all CRFs are available to centres with lit-
tle or no access to the internet. All CRFs must be com-
pleted in English and is managed by Lincoln, Paris.
Blinded and patient identifiable data are stored sepa-
rately in secure databases. All patient identifiable data
are stored by the coordinating centre.
Follow-up Data
The patient’s General Practitioner/Family Doctor is sent
a letter by post to inform them of the patient’s involve-
ment in the Eurotherm3235Trial.
Patient outcome is assessed 6 months after injury
using the GOSE questionnaire. As this is the primary
endpoint of the study, it is vital that this information is
obtained. If the patient is still in hospital 6 months after
the injury, the research nurse or investigator may visit
the patient on the ward to go through the questionnaire
with them if this is appropriate. If however the patient
has been discharged from hospital, the questionnaire is
sent to their residing address. A member of the trial
team will telephone the patient’s family doctor to find
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out their vital status before any questionnaires are sent
to the patient.
It is likely that the patient is unable to complete the
questionnaire by themselves due to the nature of their
injury. Therefore a letter will also be sent to the person
who gave consent for the patient inviting them to help
the patient to complete the form and remind them of
the study. This is sent at the same time as the GOSE
questionnaire is sent to the patient. If a response is not
received from the patient within 3 weeks, they are sent
the shorter GOS questionnaire with a covering letter.
If there is still no response, and the patient has been
discharged from hospital, an attempt will be made to
contact them directly by telephone. If the patient lacked
capacity at hospital discharge and cannot be contacted
directly by telephone, the person who consented for the
patient to be enrolled in the study is telephoned and
asked to complete the shorter GOS questionnaire over
the telephone.
If however the patient regained capacity before hospi-
tal discharge and has given consent to continue to be
involved in the follow-up phase of the study, yet cannot
be contacted directly by telephone, no further contact is
made. This process is discussed during the consent
procedure.
Staff in Edinburgh work closely with local investiga-
tors to obtain data that are as complete and accurate as
possible. Key data, such as outcome measures, are 100%
double entered into the trial database. Extensive range
and consistency checks are further enhance the quality
of the data.
Statistics and Data Analysis
Sample Size Calculation
The primary endpoint for this trial is outcome at 6
months measured by the GOSE questionnaire. The
main evidence on therapeutic hypothermia has been
gathered by six meta-analyses published between the
years 2000 and 2008. These included varying numbers
of clinical trials and examined each trial based on an
assessment of the quality of randomisation and blinding
procedures. All meta-analyses found a trend to positive
effects of hypothermia on neurological outcome, but sta-
tistical significance was reached in only two [37,38].
A major reason for the failure of previous Phase III
trials in TBI has been that they have typically been
powered to detect an absolute decrease in poor out-
come of around 10%. This is an unrealistic target in
view of the enormous heterogeneity of the TBI popula-
tion. A more modest 7% absolute decrease remains
clinically relevant and is more realistic as a hypothe-
sised treatment effect (corresponding to an odds ratio
of 0.75). Two groups of 815 give 80% power at the 5%
significance level (2-sided) to detect a decrease in poor
outcome from 60% to 53% and two groups of 900
would give 83% power to detect the same difference at
the same significance level. We aim to enrol 1800
patients in the main trial to allow for loss to follow up.
Importantly, we have been conservative with the power
calculation to reduce the chance of conducting another
underpowered trial in this field.
Proposed Primary Analysis
A detailed Statistical Analysis Plan (SAP) setting out full
details of the proposed analyses will be finalised before
the trial database is locked for analysis. The primary
analysis will follow these principles:
• The analysis will be undertaken on the ‘intention-
to-treat’ principle.
• The estimated treatment effect will be presented
along with its corresponding 95% confidence
interval.
• The analysis of the primary outcome measure, the
6 month GOSE, will exploit the ordinal nature of
the outcome scale. It is currently an active research
question in both TBI and stroke trial methodology
which approach to use to analyse such ordinal out-
come scales, the two main options being ‘shift analy-
sis’ and the ‘sliding dichotomy’. The preferred
approach will be declared in the SAP, taking into
account the results of current on-going methodolo-
gical research.
• The primary analysis will be adjusted for key base-
line covariates, to be specified in the SAP. The unad-
justed analysis will also be presented as a sensitivity
analysis.
• All interim efficacy analyses reviewed by the inde-
pendent Data and Safety Monitoring Committee will
be interpreted according to the strict Peto-Haybittle
guideline so that no adjustment is required to the
final p-value to allow for the multiple testing.
Other Planned Analyses
A priori sub-group analysis will be presented testing the
relationship between minimisation factors including: age
<45 years, admission post resuscitation Glasgow Coma
Score motor response <2, time from injury <12 hours
and outcome. The analysis will test for interaction
effects, and stricter levels of statistical significance (p <
0.01) will be sought, reflecting the exploratory nature of
these subgroup analyses. Only the primary outcome
measure will be used in these analyses.
Other exploratory and observational studies will be
conducted by some centres. These sub-studies will be
run by local Investigators and will require approval by
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the trial management and steering committees together
with further ethical approval. All sub-studies must also
have secured external funding.
Economic Analysis
The undertaking of economic data collection and analy-
sis will be dependent on obtaining external funding.
Details of this analysis will be added when external
funding is obtained.
Adverse Events
The only serious adverse events to be collected are:
• Bleeding - defined as a new haemorrhage requiring
≥2 units of packed red cells.
• Cardiovascular instability - defined as a systolic
blood pressure <90 mmHg for ≥30 minutes [37].
Terminal hypotension is not be collected.
• Thermal burns >5% of body surface area using the
Lund-Browder Chart.
• CPP < 50 mmHg for ≥15 minutes.
Trial Management and oversight arrangements
Project Management Group
The trial will be coordinated by a project management
group, consisting of the grant-holder and Chief Investi-
gator in Edinburgh, Trial Managers and advisers.
Trial Management
The trial office is associated with the Edinburgh Clinical
Trials Unit in the University of Edinburgh and gives day
to day support to the clinical centres. Trial office staff
are responsible for all aspects of trial management.
These responsibilities include providing research advice
and support to all centres, ensuring the timely comple-
tion of CRFs in collaboration with all centres, data
checking and analysis. The trial office staff are also be
responsible for the production of progress reports for
the data and safety monitoring committee (DSMC), trial
steering committee (TSC), ethics committees and the
European Society of Intensive Care Medicine (ESICM)
who are funding the study. Publication and dissemina-
tion of the study results will be coordinated by the Edin-
burgh Clinical Trials Unit in collaboration with the
Chief Investigator and Principle Investigators.
A senior Trial Manager oversees the study and is
accountable to the Chief Investigator. Two Trial Man-
agers supervise the day to day conduct of the trial,
including: initiation of trial centres, ensuring training
records are maintained and updated, supervision and
support of all trial staff, site visits to all participating
centres, regularly liaising with all trial investigators,
monitoring of centres and site closures. The Secretary/
Data Clerk is responsible for all administrative responsi-
bilities of the trial, including: manual data entering from
paper CRFs, monitoring response to follow up question-
naires, following up missing data queries and non
responses to questionnaires with the local investigators.
The statistical and scientific integrity of a major clini-
cal trial is enhanced by incorporating three distinct sta-
tistician roles: the Study Statistician who undertakes all
statistical tasks including formal analysis and reporting
of data, the DSMC and an Independent Statistician.
This Statistician is truly independent having no trial
involvement except producing unblinded interim reports
for the DSMC at specified time periods.
Subject to additional funding being obtained, a health
economist is responsible for the development of the
data collection forms required for the economic evalua-
tion, the analysis of economic data and the preparation
of the economic evaluation component of the final
report.
An IT programmer has established a database man-
agement system for efficient conduct of the trial includ-
ing the randomisation, timely despatch of
questionnaires, automatic form monitoring, data valida-
tion and cleaning.
Trial Steering Committee
The TSC oversees the conduct and progress of the trial.
Other members of the trial management group may
attend as observers at the invitation of the Chair of the
steering committee.
Data and Safety Monitoring Committee
An independent DSMC has been established to oversee
the safety of the trial participants. During the period of
recruitment to the trial, interim analyses will be sup-
plied, in strictest confidence, to the DSMC together
with any other analyses that the committee may request.
In the light of these analyses, the DSMC will inform
the TSC if, in the opinion of the committee, the rando-
mised comparison in the trial has provided either:
a) proof beyond reasonable doubt that for all or some
types of patients, the intervention is clearly indicated.(or
contraindicated) in terms of a net reduction in morbid-
ity and mortality across groups. (Appropriate criteria for
proof beyond reasonable doubt cannot be specified pre-
cisely. A difference of at least three standard deviations
in the interim analysis of a major endpoint may be
needed to justify halting, or modifying, such a study pre-
maturely. If this criterion were to be adopted, it would
have the practical advantage that the exact number of
interim analyses would be of little importance, and so
no fixed schedule is proposed (Peto R et al Br J Cancer
1976; 34: 584-612).
b) evidence that might reasonably be expected to
influence materially the care of people who require ICP
management in ICU by clinicians who know the results
of this and comparable trials.
c) Futility of enrolment.
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The TSC will then decide whether or not to modify
recruitment to the trial. Unless this happens, the TSC,
project management group, clinical collaborators and
trial office staff will remain blinded to the interim
results. The conduct of the DSMC is according to the
DAMOCLES principles [48].
Inspection of Records
Principal investigators and institutions involved in the
study will permit trial related monitoring, audits,
research ethics committee review and regulatory inspec-
tion(s). In the event of an audit, the investigator agrees
to allow the sponsor, representatives of the sponsor or
regulatory authorities direct access to all study records
and source documentation.
Study Monitoring
The study will be monitored on behalf of the Co-Spon-
sors by the Trial Managers. Site staff should be available
to facilitate the monitoring visits and must ensure that
all required documentation is available for review.
Study initiation visits are carried out at all sites before
recruitment commences at that site. Site monitoring is
carried out in sites that recruit more than 10 patients
throughout the duration of the trial. During these moni-
toring visits, the Trial Manager(s) carry out Source Data
Verification of trial data, verification of informed con-
sent forms and ensure the completeness of the Investi-
gator Site File. Site monitoring is not be carried out
routinely for sites recruiting small numbers of patients.
Central quality control checks of trial data are however
be carried out as described in section 6.0. Where central
quality control of data identifies a problem with data
collection at any site, or if the Chief Investigator and/or
Co-Sponsors have concerns surrounding the quality or
validity of the trial data at any site, a site monitoring
visit will be conducted.
Serious breaches in the study protocol and/or Good
Clinical Practice identified through trial monitoring
will be notified immediately to the Co-Sponsors
and appropriate corrective action will be taken and
documented.
Discussion
The Eurotherm3235Trial is the result of a Delphi exer-
cise surveying ESICM member’s views on research prio-
rities and started in January 2009 with protocol
development. This trial is therefore unique, being identi-
fied as a priority by members of a scientific society and
funded, independent of industry, by the same scientific
society.
The burden of bureaucracy that investigators now
have to face to conduct clinical trials is larger than ever
before. One particular aspect of recent legislation
delayed the development of the Eurotherm3235Trial
database and management of potential legislative
impediment (Commission Nationale De L’informatique
Et Des Libertés). This has meant that the data server(s)
are now hosted in the University of Edinburgh (UoE).
The database went live on April 9, 2010 and prior to
this, the trial could not randomise patients outside of
Edinburgh.
Detailed contracting is now necessary in all academic
clinical trials. The contracts required for the Euro-
therm3235Trial include:
• the financial contract between ESICM and the
UoE;
• the provision of the trial database between Lincoln,
ESICM and the UoE;
• clinical site agreements between the UoE and each
recruiting centre (including financial agreement);
• separate contracts for the UK and international
sites including Italy, Germany, Russia, Hungary and
Greece, required to incorporate the Laws of each
participating country. International contracts have
been translated to a legal standard then similarly
back-translated to ensure consistency whichtakes
approximately 6 weeks;
• a service level agreement has between the Chief
Investigator and the UoE for the data stored in
Edinburgh.
The trial has already achieved many milestones. It is
registered with the European registry of trials (http://
www.controlled-trials.com ISRCTN34555414). Sponsor-
ship has been agreed: the trial is co-sponsored by the
UoE and NHS Lothian in the UK and the UoE outside
the UK. Insurance for non-negligent harm has been pro-
vided by the UoE for European and Australasian centres
but the associated high per-claim-deductable for USA
centres has slowed progress in North America. Research
ethics committee approval was obtained in Scotland and
England in June 2009 and Hungary, Eire, Estonia, Rus-
sia, Italy and Germany in May-July 2010, and submis-
sions are well advanced in Greece, Portugal and
Belgium. National Institutes for Health Research Portfo-
lio Adoption was achieved following a complex and
time consuming process in the UK. This does however
make the trial more attractive to UK centres. Trial doc-
umentation has been translated into various European
languages including Italian, French, German, Dutch,
Estonian, Russian, Hungarian, Greek, Flemish and
Portuguese.
The current emphasis is on developing the recruit-
ment infra-structure, which is ongoing. This effort
required an extremely high level of input; however, the
Eurotherm3235Trial is in good shape for the ongoing
challenge of the recruitment phase as a result of the
hard work of the Trial Coordinating Team, together
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with Investigators, in establishing the recruitment infra-
structure. This work will continue to be of highest
priority in order to maximise recruitment.
The trial is open to all ICUs with TBI patients and we
encourage clinicians to visit the trial website, register
an interest and complete a centre survey. The Trial
Coordinating Team are available to help you with regu-
latory submissions. The results of the Eurotherm3235-
Trial will be relevant to all those who look after patients
with TBI. The trial can only be successful if clinicians
and nurses from ICUs worldwide contribute. We thank
the large number of Investigators who are contributing
to this trial already.
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